Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2026)
Supernus Pharmaceuticals' Research & Development came in at $29.46 million for Q2 2026, up 33.2% from $22.12 million a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Supernus Pharmaceuticals reported Research & Development of $108.77 million, up 1.9% year-over-year; for FY2025, it came in at $106.24 million, down 2.4% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 6.9% (FY2020 to FY2025).
- Going back by year, Research & Development was $108.8 million in FY2024 (+18.8%), $91.59 million in FY2023 (+22.9%), $74.55 million in FY2022 (-17.6%) and $90.47 million in FY2021 (+19.1%).
- The Q2 2026 figure represents the highest quarterly Research & Development since Q1 2021.
- Year-over-year, Research & Development increased in five of the last seven quarters, with growth averaging 10.7%.
- The fastest year-over-year change in Research & Development over five years came in Q2 2023 (growth of 48.8%), and the weakest in Q1 2022 (a decline of 39.2%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Supernus Pharmaceuticals | 2.42 Bn | 1.07 Bn | 185.39 Mn | 29.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.46 Mn |
| Dec 31, 2025 | 27.83 Mn |
| Sep 30, 2025 | 29.37 Mn |
| Jun 30, 2025 | 22.12 Mn |
| Mar 31, 2025 | 26.93 Mn |
| Dec 31, 2024 | 28.65 Mn |
| Sep 30, 2024 | 29.04 Mn |
| Jun 30, 2024 | 26.18 Mn |
| Mar 31, 2024 | 24.93 Mn |
| Dec 31, 2023 | 23.35 Mn |
| Sep 30, 2023 | 22.66 Mn |
| Jun 30, 2023 | 24.38 Mn |
| Mar 31, 2023 | 21.21 Mn |
| Dec 31, 2022 | 17.77 Mn |
| Sep 30, 2022 | 19.55 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 20.84 Mn |
| Dec 31, 2021 | 21.08 Mn |
| Sep 30, 2021 | 19.65 Mn |
| Jun 30, 2021 | 15.46 Mn |
API Access
Supernus Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();